Curated News
By: NewsRamp Editorial Staff
July 07, 2026

Oragenics Activates All Australian Sites for Concussion Trial

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Oragenics activates all three Australian sites for concussion drug trial, targeting a key market advantage with no serious adverse events.
  • Oragenics advances ONP-002 through Phase IIa in Australia with FDA guidance request for U.S. clinical development plan.
  • Oragenics moves closer to a first-in-class treatment for concussion, potentially improving outcomes for brain injury patients worldwide.
  • Oragenics uses a proprietary intranasal delivery platform to target neurological conditions like Parkinson's and Alzheimer's.

Impact - Why it Matters

This news matters because traumatic brain injury (TBI) affects millions worldwide, yet there are no FDA-approved treatments specifically for concussion. Oragenics' ONP-002, delivered via a novel intranasal platform, could become the first approved therapy for mild TBI, potentially transforming acute concussion management. The progression to Phase IIa trials and engagement with the FDA signals a significant step toward addressing this unmet medical need, offering hope for faster recovery and reduced long-term complications for patients. For investors, the upcoming data readout and U.S. regulatory path represent key milestones in the company's development.

Summary

Oragenics (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants, following the activation of Royal Adelaide Hospital. The company reported that no serious adverse events have been observed in dosed participants to date, and it continues to target a Phase IIa data readout in the fourth quarter of 2026. Additionally, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002, supporting its goal of submitting an Investigational New Drug application in the fourth quarter of 2026.

Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. Oragenics is committed to addressing significant unmet medical needs in neurological care.

The news was disseminated through BioMedWire (“BMW”), a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BMW is part of the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit oragenics.com or the company's newsroom at https://ibn.fm/OGEN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Activates All Australian Sites for Concussion Trial

blockchain registration record for this content.